乳腺癌 z-bo 2020-09-21 398

　　A joint team from Canada and the United States has investigated and analyzed the functions of the largest breast cancer cells to discover dozens of new uses of existing drugs, new targets for drug development, and new drug combinations. The results of this study can also be used to develop new drug candidates for other cancers and to clarify the drug resistance mechanism of cancer cells.

　　Toronto Princess Margaret Cancer Center and NYU Langon Medical Center have formed a collaborative team to discover how genetic changes in breast cancer cells interfere with the signaling pathways necessary for growth and survival. These approaches may be the targets of new drugs or combinations of existing drugs. Researchers have improved new statistical methods to correlate genetic changes in cancer cells with the complex functions that cancer cells rely on most to identify genes required for specific breast cancer subtypes. I said it can be recognized. The research team screened 77 breast cancer cell lines. This large enough sample size represents many subtypes of breast cancer. By scoring the results of gene knockout studies in these cell lines, the researchers identified some of the most important cancer growth candidate genes. This study proposes several signaling pathways for further study of each breast cancer subtype, and identified some candidate genes that have not yet mastered the survival role of breast cancer cells.

　　In addition, the research team has also discovered the combination of genes required for cells that are sensitive or resistant to 90 anticancer drugs. The researchers said that only a few patients have completed genome-wide sequence analysis of cancer cells, and these results have not yet worked. The ultimate goal of the research is to fully understand the development roadmap of each cancer cell, discover molecular targets, and determine which new therapy and which patient groups are most likely to respond to this therapy.